TY - JOUR
T1 - Bispecific antibodies for viral immunotherapy
AU - Nyakatura, Elisabeth K.
AU - Soare, Alexandra Y.
AU - Lai, Jonathan R.
N1 - Funding Information:
We gratefully acknowledge NIH grant U19-AI109762 (Centers of Excellence for Translational Research) and an Irma T. Hirschl/Monique Weill-Caulier Career Scientist Award (to J.R.L.). E.K.N. was supported by a DAAD (Deutscher Akademischer Austausch Dienst, German Academic Exchange Service) fellowship.
Publisher Copyright:
© 2017 Taylor & Francis.
PY - 2017/4/3
Y1 - 2017/4/3
N2 - Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies. While the bispecific antibody approach has been applied widely to targets for indications such as cancer and inflammation, the development of such agents for viral immunotherapy is only now emerging. Here, we review recent advances in the development of bispecific antibodies for viral immunotherapy, highlighting promising in vitro and in vivo results.
AB - Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies. While the bispecific antibody approach has been applied widely to targets for indications such as cancer and inflammation, the development of such agents for viral immunotherapy is only now emerging. Here, we review recent advances in the development of bispecific antibodies for viral immunotherapy, highlighting promising in vitro and in vivo results.
KW - antibody engineering
KW - antibody therapeutics
KW - antiviral
KW - bifunctional antibodies
KW - bispecific antibodies
KW - immunotherapy
KW - passive immunization
KW - virology
UR - http://www.scopus.com/inward/record.url?scp=85021308971&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021308971&partnerID=8YFLogxK
U2 - 10.1080/21645515.2016.1251536
DO - 10.1080/21645515.2016.1251536
M3 - Review article
C2 - 27786606
AN - SCOPUS:85021308971
SN - 2164-5515
VL - 13
SP - 836
EP - 842
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
IS - 4
ER -
